Eli Lilly & Co., down $1.60 at $49
The drugmaker is planning another study for a potential Alzheimer's treatment, delaying possible FDA approval and the drug's sale.
Aetna Inc., up $1.43 at $45.91
A Goldman Sachs analyst says the health insurer's initial forecast for 2013 may have been stronger than some investors expected.
Teva Pharmaceutical Industries Ltd., down $2.20 at $39.47
Some analysts are disappointed that the drugmaker didn't give more specific details about the drugs it's working on.
YM BioSciences Inc., up $1.25 at $2.88
The Canadian drug developer is being bought by Gilead Sciences for $2.95 per share, an 81 percent premium.
For the more heavily traded Class B shares of Berkshire Hathaway Inc., up $2.05 at $89.32
Warren Buffett's company is paying $1.2 billion to buy back 9,200 Class A shares, and the board approves higher prices for future buybacks.
Coinstar Inc., up $1.15 at $51.96
The company's DVD kiosk operator, Redbox, is starting an unlimited streaming-video plan for $8 a month in a challenge to Netflix.
Charles River Laboratories International Inc., down $3.65 at $35.65
The medical research equipment provider's profit prediction for 2013 falls short of the average estimate of Wall Street analysts.
Ziopharm Oncology Inc., down 27 cents at $4.17
A Jefferies analyst thinks the drug developer's experimental cancer drug may not be effective enough to win regulatory approval.